Trial Profile

Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sacituzumab govitecan (Primary)
Indications Bladder cancer; Carcinoma; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 May 2025 Planned primary completion date changed to 11 Apr 2026
12 Feb 2025 Planned End Date changed from 11 Apr 2027 to 1 Oct 2027.
02 Dec 2024 Timeframe for primary endpoint 'Phase 2: Overall Response Rate' has been changed from up to 12 months to up to 30 months.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com